ArticleCell death & disease2018

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.

Xiaoyuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.